Welcome to our dedicated page for Monte Rosa Therapeutics SEC filings (Ticker: GLUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monte Rosa Therapeutics filings document a clinical-stage biotechnology company developing molecular glue degrader medicines and reporting as a Nasdaq-listed operating company. Its 8-K filings cover financial results, Regulation FD clinical disclosures, material-event updates and capital-structure matters tied to common stock and registration statements.
The company’s proxy materials disclose annual meeting proposals, director elections, auditor ratification and governance practices. Other filings address executive officer and principal accounting officer transitions, compensatory arrangements, shareholder voting matters, clinical program disclosures for MRT-8102 and MRT-2359, and risk areas associated with drug development, financing and public-company compliance.
Monte Rosa Therapeutics received an amended ownership filing showing T. Rowe Price Associates, Inc. beneficially owns 8,861,282 shares of Common Stock, representing 10.5% of the class as of 06/30/2026. The filing lists sole voting power for 8,856,521 shares and sole dispositive power for 8,861,282.
Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson reported an exercise-and-sell transaction in company stock. On July 6, 2026, she exercised options to acquire 6,000 shares of common stock at $6.14 per share and sold a total of 6,000 shares in open-market trades, including 400 shares at $24.13 and additional shares at a weighted average price of $23.2495 within a range of $22.97 to $23.65. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After the trades, she directly holds 67,845 shares of common stock.
Monte Rosa Therapeutics director-linked funds restructured their holdings without market trades. On July 1, 2026, New Enterprise Associates 17, L.P. made a pro rata distribution of 1,000,000 shares of Monte Rosa Therapeutics common stock to its general and limited partners for no consideration. NEA Partners 17 both received and later distributed 15,000 shares, also for no consideration. Director Ali Behbahani is a manager of the related general partners and disclaims beneficial ownership of shares in which he has no pecuniary interest, so these entries reflect internal reallocations among NEA-affiliated entities rather than open-market buying or selling.
Monte Rosa Therapeutics major holder New Enterprise Associates has updated its ownership details. NEA 17 now holds 6,692,298 shares of Monte Rosa common stock, representing 7.9% of the company’s outstanding shares based on 84,479,418 shares outstanding as of May 1, 2026.
On July 1, 2026, NEA 17 made a pro rata distribution of 1,000,000 Monte Rosa shares to its general partner and limited partners for no consideration. NEA Partners 17 briefly received 15,000 shares in this distribution, then distributed those 15,000 shares the same day, including 11,830 shares to an entity for which certain NEA executives may be deemed beneficial owners. Those indirectly received shares were sold on July 2, 2026 as described in Schedule A.
The filing also notes that Ali Behbahani holds options to purchase 135,432 shares exercisable within 60 days, and that several named individuals each ceased to beneficially own 5% or more of Monte Rosa’s common stock as of April 1, 2026.
Monte Rosa Therapeutics Chief Medical Officer Filip Janku exercised stock options and sold shares in a pre-planned transaction. On June 30, he exercised options to acquire 5,407 shares of common stock at $13.41 per share, then sold 5,407 shares at $24.50 per share in an open-market sale pursuant to a Rule 10b5-1 trading plan adopted on March 4, 2026. After these transactions, he directly owned 60,612 shares of common stock, including 620 shares acquired through the company’s 2021 Employee Stock Purchase Program on June 30, 2026.
GLUE affiliate submitted a Form 144 notice disclosing proposed and recent sales of Common Stock, including an exercise of stock options and multiple 10b5-1 sales in late June 2026. The filing lists an option exercise of 5,407 shares on 06/30/2026 and 10b5-1 dispositions of 30,000, 11,845, and 6,000 shares on 06/24/2026, 06/23/2026, and 06/29/2026 respectively, with gross proceeds shown for each sale.
Monte Rosa Therapeutics Chief Medical Officer Filip Janku reported an exercise-and-sell transaction in company stock. He exercised stock options to acquire 6,000 shares of Common Stock at $7.56 per share and on the same date sold 6,000 shares at $22.95 per share in an open-market transaction.
After these transactions, Janku directly holds 59,992 shares of Common Stock and retains 60,000 stock options that remain outstanding and fully vested. The company notes these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2026, indicating they were scheduled in advance rather than timed discretionarily.
Monte Rosa Therapeutics director Anthony M. Manning reported an exercise-and-sale transaction in the company’s common stock. He exercised stock options to acquire 10,000 shares of common stock at an exercise price of $4.16 per share, then completed an open-market sale of 10,000 shares at $23.11 per share on the same date.
Following these transactions, his reported direct common stock holdings were 0 shares, while a stock option position for 2,100 shares remained outstanding, with an expiration date in 2034. The filing characterizes the stock transaction as an open-market sale.
Insider transaction filing for GLUE. A filer reported the exercise of 6,000 stock options and concurrent sale activity under an established trading arrangement. The record shows 10b5-1 sales of 30,000 shares on 06/24/2026 for $642,681 and 11,845 shares on 06/23/2026 for $239,522.50. The transactions are reported for sale on NASDAQ.
Anthony M. Manning reported sale of 10,000 shares of Common Stock of GLUE. The sale occurred on 05/21/2026 for aggregate proceeds of $180,100.00. The filing also lists a planned stock option exercise of 10,000 shares on 06/29/2026 with cash consideration.